NCT01944969 - Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Major Depressive Disorder

Interventions

DRUG

Brexpiprazole

1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)

Trial Locations (1)

US008, Orlando